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Abstract
Purpose: To assess the feasibility of adding hyperthermia to an original method of organpreserving brachytherapy treatment for locally advanced head and neck tumors.
Methods and Materials: The method involves organ-preserving tumor resection and adjunctive
high-dose-rate (HDR) brachytherapy delivered via afterloading catheters. These catheters are
embedded in a polymeric implant prepared intraoperatively to fill the resection cavity, allowing
precise computer planning of dose distribution in the surrounding at-risk tumor bed tissue.
Theoretical and experimental analyses address the feasibility of heating the tumor bed implant by
coupling energy from a 100 kHz magnetic field applied externally into ferromagnetic particles,
which are uniformly distributed within the implant. The goal is to combine adjuvant hyperthermia
(40-45°C) to at-risk tissue within 5 mm of the resection cavity for thermal enhancement of radiation
and chemotherapy response.
Results: A five-year relapse free survival rate of 95.8% was obtained for a select group of 48 male
patients with T3N0M0 larynx tumors, when combining organ-preserving surgery with HDR
brachytherapy from a tumor bed implant. Anticipating the need for additional treatment in patients
with more advanced disease, a theoretical analysis demonstrates the ability to heat at-risk tissue up
to 10 mm from the surface of an implant filled with magnetically coupled ferromagnetic balls.
Using a laboratory induction heating system, it takes just over 2 minutes to increase the target tissue
temperature by 10°C using a 19% volume fraction of ferromagnetic spheres in a 2 cm diameter
silicone implant.
Conclusion: The promising clinical results of a 48 patient pilot study demonstrate the feasibility of
a new organ sparing treatment for laryngeal cancer. Anticipating the need for additional therapy,
theoretical estimations of potential implant heating are confirmed with laboratory experiments,
preparing the way for future implementation of a thermobrachytherapy implant approach for organsparing treatment of locally advanced laryngeal cancer.

Keywords: locally advanced head and neck tumors, laryngeal cancer, organ-preserving surgery,
HDR brachytherapy, intraoperative hyperthermia.

Introduction
Laryngeal cancer comprises about 3% of all human cancers. The disease occurs primarily in 4060 year old males. Effective treatment of laryngeal cancer depends heavily on early detection.
However, initial tumor growth often occurs without being noticed, especially for endophytic
nodules. This explains typical late referral for medical help that leads to more than 50% of patients
having stage T3 and T4 primaries. The most common treatment for such patients is total
laryngectomy, which inevitably leads to traumatic disability without ruling out tumor recurrence.
Ongoing progress in multimodality approaches to treat laryngeal cancer (Holsinger, 2008) have led
to five-year survival rates above 90% for early detected T1-T2 stage tumors. However, five-year
survival is <60% for patients with intermediate or advanced stage disease (Rudolph et al., 2011),
which highlights the need for improved therapy.
Integration of new treatment approaches such as organ preservation surgery (Sperry et al., 2013,
Wilkie et al., 2015, Vasil'chenko et al., 2011), HDR brachytherapy (Obinata et al., 2007), and
hyperthermia (Paulides et al., 2007a, Paulides et al., 2010, Falk and Issels, 2001) have been
proposed to improve quality of life in advanced head and neck cases by saving larynx function as
well as increasing survival. Local tumor hyperthermia (temperatures of 40-45°C) is a promising
adjuvant treatment method in cancer therapy, contributing to a significant improvement of
therapeutic efficacy in sites where adequate heating is possible (Overgaard et al., 1996, Sneed et al.,
1998, Valdagni and Amichetti, 1994, Datta et al., 2016b, Datta et al., 2016a, Issels et al., 2010).
This technique is normally applied as an adjuvant to established cancer treatment modalities such as
radiotherapy and chemotherapy (Hurwitz and Stauffer, 2014, Dewhirst et al., 2015).
Depending on size and location in the body, there are many different technologies available for
heating tumors. Local hyperthermia induced by microwave radiation is often used for treatment of
tumors close to the skin surface, but penetration of effective heating is limited to about 3-4 cm.
Treatment of tumors deep in the neck with external microwave waveguide applicators has been
reported, but significant heating of overlying tissues is unavoidable (Kouloulias et al., 2014,
Amichetti et al., 1993). Penetration deeper in tissue using a phased array of microwave antennas has
been proposed (Arcangeli et al., 1984, Gross et al., 1990) and prototype arrays designed specifically
for neck tumors are currently under development (Paulides et al., 2007b, Paulides et al., 2010,
Togni et al., 2013). Radiofrequency phased-array systems are also available that can penetrate deep
in the body, but the long wavelength generates a large heat focus (Canters et al., 2009, Van Rhoon
et al., 2003, Fatehi and van Rhoon, 2008). In either case, significant heating of critical normal
tissues outside the tumor target is usually unavoidable. Alternatively, the use of ultrasound from
external transducer arrays allows precise focusing into deep tissue targets (Al-Bataineh et al., 2011,
Chen et al., 2011, Haar and Coussios, 2007, Hurwitz et al., 2014, Tempany et al., 2011), but this

approach is problematic for larynx due to the heterogeneous anatomy and proximity to air and bone
regions, which reflect or absorb ultrasound preferentially. Thus, the complex anatomy and
sensitivity of surrounding critical normal tissues severely restricts the application of external
heating technology to small head and neck tumors.
Several interstitial implant techniques allow focused heating at depth, including interstitial
radiofrequency electrodes, microwave antennas, ultrasound transducers, and several hot source
techniques based on thermal conduction (Stauffer et al., 1995). Most of these modalities require
percutaneous insertion of an array of needles or catheters to insert heat sources, power connections,
and temperature control sensors. For most head and neck tumors, maintaining an externalized array
of percutaneous catheters following surgery is painful and undesirable for the patient. One hot
source technique that overcomes these issues is the use of external magnetic fields to couple energy
non-invasively into implanted ferromagnetic needles or spheres (ferroseeds). This minimally
invasive approach has been investigated by numerous groups beginning almost 45 years ago
(Brezovich et al., 1984, Burton et al., 1971, Kobayashi et al., 1986, Stauffer et al., 1984a, Mack et
al., 1993, Tucker et al., 2000, Stauffer et al., 1984b, Atkinson et al., 1984). When these 1-2 mm
diameter ferromagnetic materials are immersed in a sub-megahertz radiofrequency magnetic field,
eddy currents are induced on the metal surface. As a result, the implants are heated by resistive
losses from the induced currents, and tissue around the implants is heated by thermal conduction
from the hot surface. Because of the rapid falloff of temperature away from small diameter heat
sources, there are steep thermal gradients around the implants, especially in tissue with high blood
perfusion. Tissue immediately adjacent to the heat sources is generally overheated, while tissue >5
mm from the implants may not be heated sufficiently (Chin and Stauffer, 1991).
One of the proposed ways to improve local tumor control and survival rates for patients with
locally advanced head and neck cancer is an original method of intraoperative HDR brachytherapy
invented at the Regional Clinical Cancer Center (RCCC) in Kemerovo, Russia (Vasil’chenko et al.,
2008, Vasil'chenko et al., 2011). This method combines laryngeal resection surgery with
brachytherapy, where a patient-specific biocompatible implant mold is formed within the resection
cavity, replacing tumor and providing precise computable locations for the HDR source. This paper
reviews the results of a clinical study using this method for treatment of 48 patients with laryngeal
cancer. With the goal of expanding this novel treatment to larger numbers of patients with more
advanced disease, we assessed the feasibility of adding hyperthermia to further enhance clinical
outcomes, by incorporating spherical ferroseeds into the same tumor bed implant and coupling heat
into the seeds via an externally applied magnetic induction field (Osintsev et al., 2013, Vasil'chenko
et al., 2013).

Methods
Surgery and Brachytherapy
Between September 2006 and June 2009, a total of 96 male patients with stage Т3N0М0
laryngeal cancer were treated at the RCCC with a novel technique. All patients signed voluntary
consent according the Fundamentals of Russian legislation on health care N5487-1 for treatment
under a protocol approved by the Ethics Committee at the Russian Center for Research in
Radiological and Surgical Technologies (St. Petersburg, Russia). All patients received external
beam radiotherapy using two lateral opposed fields measuring 6-8 × 8-12 cm2. The area inside the
90% isodose line included the larynx and potential microscopic tumor extension. A total external
beam dose of 35 Gy was delivered using 2.5 Gy/fraction, 5 times a week. Radiation therapy was
supplemented with concurrent administration of 5-fluorouracil (5-FU) as a radiosensitizer at a dose
of 250 mg/m2 intravenous, every other day.
Initial tumor response was assessed 14 days after completion of external beam radiotherapy and
5-FU administration, when acute radiation reactions had abated. From the initial group of 96 men,
48 patients (50.0%) had obvious reduction of tumor volume and were selected to continue with the
protocol. From this selected favorable patient group, keratinizing squamous cell carcinoma of the
larynx was observed in 41 patients (85.4%) and non-keratinizing cancer in 7 patients (14.6%). With
respect to tumor location, cancer of the glottis part of the larynx was most common (62.5%),
followed by cancer of the supraglottic larynx (25%), and similar involvement of two adjacent parts
of the larynx (12.5%). Exophytic tumor growth was noted in 7 patients (14.6%), infiltrative in 21
patients (43.7%) and mixed in 20 patients (41.7%). All responding patients underwent organpreservation surgery including different variants of partial larynx resection that depended on tumor
response. At the time of surgery, a custom implant was fabricated from soft pliable silicone material
that hardened in situ to fit the size and shape of the resection cavity (figure 1).

Figure 1. Schematic of organ-preserving surgery and preparation for brachytherapy treatment: (a) larynx
with tumor; (b) partially resected larynx; (c) inserted volumetric implant mold with lateral afterloading
catheters; and (4) inserted longitudinal catheter. 1 – larynx walls; 2 – tumor; 3 – implant mold; 4 –
afterloading catheters (active part marked in dark grey).

Figure 1 gives a pictorial of the surgical procedure. Following placement of a tracheostoma, the
exposed tumor is excised. After wound hemostasis, a 3D volumetric implant is created by filling the

resected tumor bed (and part of the larynx) with flexible silicone-based polymeric putty (Speedex,
Coltene Inc, Cuyahoga Falls OH) that is pressed into place by the surgeon. Polymerization typically
generates a brief mild <2C exothermic reaction. The mass becomes firm enough in about 3
minutes to hold its shape, while remaining pliable enough to insert the brachytherapy catheters and
a retraction string fastener, which enables the removal of the implant through the mouth at the end
of therapy. The solidified implant is then removed and catheters inserted into the mold, in positions
appropriate for guiding radioactive seeds to deliver brachytherapy to the tumor bed (figure 2a-b).
Ideal catheter configuration depends on size, shape and location of the tumor bed implant which is
optimized in the OR based on experience of the surgeon and radiotherapist. An axially directed
flexible catheter is least traumatic as it can be withdrawn after treatment through the tracheostoma.
Additional semi-rigid catheters exiting through the surgical scar are added as needed to improve
dose uniformity. Dosimetric planning is used to optimize the number and spacing of catheters and
source locations. The active length of each implant catheter is customized to irradiate at-risk tissues
around the resected tumor and minimize dose to surrounding organs-at-risk. The equivalence of
radiation delivery through the silicone implant material is confirmed by dosimetric measurements.
The pre-formed implant is then reinserted into the resected tumor bed, and the wound is sutured
closed around the percutaneous catheters (figure 2c).

Figure 2. Patient-specific biocompatible implant with (a) rigid lateral catheters and (b) flexible longitudinal
catheter. (c) Brachytherapy delivery with catheters connected to an HDR brachytherapy system.

After radiographic imaging of the implant, computer-assisted 3D reconstruction software is used
to segment the implant, gross tumor volume (GTV), clinical target volume (CTV), and surrounding
neck structures including organs at risk (figure 3). The resulting images are transmitted to the HDR
planning program through a projection scanner. The planning target volume includes the resected
tumor bed with a margin of ~5 mm around the implant.
A single dose of 10 Gy minimum to the implant/tissue interface is delivered immediately after
surgery (usually within one hour) by means of the GammaMed PlusTM brachytherapy apparatus,
and then the catheters are removed from the implant. Following delivery of radiation, the implant is
left in place mainly as an obturator to avoid negative post-operative and post-radiation reactions

such as larynx stenosis. Fourteen days after surgery, the implant is removed from the lumen of the
larynx through the mouth by pulling on the retraction string fastened to the implant.

Figure 3. (a) 3D reconstructed image of patient with two catheter implant mold surgically placed in partially
resected larynx; (b) Segmented 3D image used for HDR treatment planning showing target volume (yellow)
with two brachytherapy catheters and critical normal tissue structures to avoid.

Treatment efficacy is assessed by the following criteria: (1) degree of recovery of laryngeal
function in terms of swallowing, breathing and speech; (2) incidence and character of postoperative
complications; and (3) duration of disease-free period after treatment. The nasogastric tube removal
and patient’s ability to take adequate oral nutrition are indications of the recovery of laryngeal
function, including effective separation of breathing and swallowing. The rehabilitation of breathing
is characterized by the time of decannulation after the multimodality treatment.

Hyperthermia feasibility
In order to enhance clinical responses in patients with more advanced head and neck cancers, we
investigated the feasibility of adding local hyperthermia. For optimum compatibility with the
brachytherapy implant approach, we choose the magnetic induction heating technique because it
eliminates the need for power or thermal probe connections to the implant. In this method,
ferromagnetic balls are embedded in the implant and heated inductively using an externally applied
100 kHz magnetic field (figure 4). The raw silicone implant material has a soft putty-like
consistency prior to polymerization and once properly mixed, the ferromagnetic particles are
distributed uniformly throughout the material.

Since the implant solidifies quickly in situ or

following a short heat exposure, no sedimentation or separation of the embedded ferromagnetic
particles occurs even during subsequent heating. Thus, the ferromagnetic particles remain uniformly
distributed throughout the implant mold and thereby produce uniform temperature of the implant
surface, unlike needle or catheter based interstitial heating technologies that generate very hot and
cold regions between heat sources.

For initial laboratory testing of this approach, we chose stainless steel balls of 1 mm diameter as
ferromagnetic particles dispersed throughout a spherically shaped silicone mold with 2 cm
diameter. This laboratory implant was inserted at the center of an air core induction coil with 10
turns, 5 cm diameter, and 8 cm axial length. With 20 W of power applied at 100 kHz, a magnetic
field of 500 A/m was obtained in the region of the ferromagnetic seed filled polymeric mass.
Temperatures were measured at the implant center with Type E thermocouples (chromelconstantan) with 0.1 mm diameter wires aligned perpendicular to the field. RF shielding of the
thermocouple wires was provided by thin grounded aluminum tubes, allowing essentially artifact
free thermometry in the 500 A/m field.

Figure 4. Schematic of magnetic induction heating procedure. 1 – Modified implant with ferromagnetic
material dispersed uniformly throughout the silicone implant alongside brachytherapy catheters; 2 –
induction coil to generate magnetic field; 3 – RF power generator (~100 kHz); 4 – computer controller.

To estimate the heating characteristics of this method, we consider a simple model of a spherical
implant mold with radius Ri = 1 cm, in which the conductive ferromagnetic spherical particles of
radius Rs are uniformly distributed. For an implant in a magnetic field of amplitude Hm and
frequency ω, heat is produced in each sphere due to induced eddy currents. Provided Rs<<Ri and
sufficiently high density of conductive ferromagnetic particles, the steady state temperature
distribution inside the implant (Ti) and in the tissue around the implant (Tt) are described by the heat
equation and Pennes’ equation (Pennes, 1948), respectively:
ki  2Ti  Qi  0 ,

(1)

kt  2Tt  bt cb (Tt  Ta )  mt  0 ,

(2)

where k is thermal conductivity; Q is the heat generated by the inductively coupled ferromagnetic
spheres (in W/m3) assumed to be homogenously distributed within the implant; ωb is blood

perfusion rate of surrounding tissue (in kg/s/m3); cb is specific heat capacity of blood (3617 J/kg/K);
Ta is arterial temperature (37°C); m is the heat generated in tissue due to metabolism (in W/m3); and
the indexes i and t correspond to the polymeric implant and tissue, respectively.
Equations (1) and (2) can be solved directly considering the following boundary conditions:
finite temperature at the implant center (∂Ti/∂r = 0 at r = 0); temperature and heat flux continuity at
the implant/tissue interface Ri; Tt = T0 at a distance Rext sufficiently distant to be unaffected by the
implant heat source (e.g. several centimeters), and body core temperature T0 = 37°C. The solution
of equation (2) has been derived previously for these boundary conditions (Rodrigues et al., 2013).
Applying this to the current problem, the analytical solution for temperature distribution inside the
implant and in tissue around the implant may be estimated to first order considering no blood
perfusion or metabolism. Using a spherical coordinate system, the solution yields:

Ti (r )  

Qi 2 Qi Ri3 2ki ( Rext  Ri )  Rext kt
r 
 T0 , and
6ki
6ki kt
Ri Rext

Tt (r ) 

Qi Ri3  1 1
 
3kt  r Rext


  T0 .


(3)

(4)

To achieve therapeutic radiosensitization from moderate temperature hyperthermia, temperature
in the at-risk tissue target should be in the range 40-45°C (Dewhirst et al., 2015). This is achieved
by imposing a temperature of 45°C at the interface between the implant and tissue, which will heat
the surrounding tissue target by thermal conduction. Using equation (4) and the latter condition, i.e.
Ti(Ri) = 45°C, the heating power in Watts Pi = Qi ∙Vi (with Vi the implant volume) required from
within the implant to heat the surrounding at-risk tissue is:

Pi 

24kt RextVi
R02 ( Rext  R0 )

(5)

where we use T0 = 37°С as core temperature.
The tumor bed tissue is not homogeneous however. The implant in neck is surrounded by
heterogeneous tissue that includes low perfusion tissues such as fat and bone (ωb ~ 0.3 kg/s/m3) and
higher perfusion tissues such as muscle (ωb ~ 0.7 kg/s/m3). In addition, heating the tumor bed
>40°C will increase blood perfusion eight-fold or more, reaching over 6 kg/s/m3 in heated muscle
(Sekins et al., 1984, Hasgall et al., January 13th, 2015). In order to bracket the range of expected
heating profiles, we determine the temperature for a range of blood perfusion scenarios: ωb = 0
kg/s/m3 using equation (3); ωb = 0.7 kg/s/m3 (basal perfusion); and ωb = 6 kg/s/m3 (active
perfusion) using the analytical solution derived by Rodrigues et al. (Rodrigues et al., 2013). In
addition, we determine the therapeutic penetration depth, defined by the distance into tumor bed
where Tt ≥40°C.

The amplitude of the magnetic field (Hm) required to produce the required amount of heat from
the implant is a function of the heat generated by eddy currents in each steel ball, defined here as Ps
= QiVs/(in Watts) with Vs being the volume of each steel ball of radius Rs and  being the volume
fraction of steel inside the implant mold of radius Ri. The magnetic field amplitude can then be
determined (Stauffer et al., 1984b):

Hm 

Ps
3 R

2
s

20  / 

(6)

where  is electrical conductivity,  is a magnetic permeability, 0= 410–7 H/m,  = 2f and f is
magnetic field frequency.

Results
Surgery and Brachytherapy
Treatment with this technique was well tolerated as previously reported.

The nasogastric tube

was removed within 2 days in all 48 patients. Proper laryngeal function was preserved entirely in 44
patients (91.7%). Four patients (8.3%) were not able to swallow liquid food. In terms of breathing,
47 patients (98%) were decannulated 2 to 6 months after completion of the laryngeal cancer
treatment. One patient (2.1%) developed cicatricial stenosis of the larynx and could not be
decannulated, even after surgical treatment of his laryngeal stenosis. Reconstruction of tracheofistulas formed during healing of the tracheostomy was performed in 8 patients (16.7%) within 6
months to 2 years. The 3-year relapse-free survival rate reported in 2011 was 95.8%, i.e., 46
patients were alive with no evidence of local recurrence (Vasil'chenko et al., 2011). Disease
progression occurred in 2 patients (4.2%) within 6 months. These two patients underwent total
laryngectomy with one dying of distant metastases. With an additional 24 months of follow-up,
there were no additional cases of disease progression such that the 5-year relapse free survival rate
was 95.8% (Vasil'chenko et al., 2013).
Figure 5 shows the isodose distributions within the planning target volume generated by the
ABACUS planning system, with shaded regions overlaid to indicate the extent of implant and
tumor bed tissue target. Typically, brachytherapy was planned to achieve a minimum target dose of
10 Gy at the implant border. Figure 5 demonstrates symmetric distribution of active points inside
the implant. If the target volume around the implant is non-symmetric, as it is for example in figure
1, the surgeon will adjust position of the catheters appropriately and the radiotherapist will preplan
the active points to ensure conformality of dose to the target region. Radiation preplanning is
straightforward due to tissue-equivalence of the implant material for radiation.

Figure 5. Isodose distribution from the lateral (a) and longitudinal (b) catheters.

Hyperthermia feasibility
The feasibility of adding hyperthermia via the brachytherapy implant was assessed theoretically
and experimentally. For a 2 cm diameter spherical implant (Ri = 1 cm) placed in a tumor bed with
thermal conductivity similar to muscle (kt = 0.5 W/m/K) and surrounded by a 37C tissue boundary
at Rext = 5cm, the power absorption within the implant required to heat the surrounding tumor bed
may be calculated from equation (5) to be Pi = 0.6 W, before considering the cooling effects of
blood perfusion. The thermal conductivity of the implant is estimated to be ki = 10.2 W/m/K for a
volume fraction of metal spheres of  = 0.2, as determined from the volume-weighted average of
silicone (0.2 W/m/K) and steel (50.2 W/m/K). Accounting for the heat lost due to blood perfusion,
the required power from the implant increases to 0.9 W for basal perfusion (resting muscle) and 1.6
W for active perfusion (highly-perfused soft tissue at elevated temperature). Figure 6a presents the
expected temperature distribution in and around a 2 cm diameter implant heated to a surface
temperature of 45C, for a bracketing range of tissue perfusion expected in the human neck. The
penetration of therapeutic heating (>40C) extends out from the implant surface into surrounding
tumor bed 10 mm if no perfusion, 6.1 mm with basal perfusion rate, and 3.2 mm with the

anticipated upper limit active perfusion rate. Figure 6b shows the implant surface temperatures
required to obtain the minimum therapeutic temperature of 40C throughout a 5 mm rim of tumor
bed tissue for the same three perfusion levels. Table 1 gives a summary of calculations regarding
the required implant power absorption from the magnetic field, as well as the resultant heating of
tumor bed tissue for a bracketing range of possible tissue perfusion levels. At temperatures
exceeding 45-48C, we can expect tissue damage to reduce blood perfusion below the high
perfusion level shown in red in figure 6, which would decrease the implant surface temperature
required to get 40C throughout a 5 mm rim of target tissue.

Figure. 6. Temperature profiles generated by a 2 cm diameter silicone implant with 1 mm diameter steel
balls uniformly distributed with a volume fraction of 0.2: (a) analytical solution of equation (4), where both
blood perfusion and metabolic heat rate are set to zero; and two more cases with basal blood perfusion (0.7
kg/s/m3) and active blood perfusion (6.2 kg/s/m3) where mt = 988 Wm3; (b) theoretical penetration of heat
around the implant, showing required implant surface temperatures to achieve minimum therapeutic tumor
bed temperature of 40C at 5 mm distance from implant for the three blood perfusion cases.

Using a volume fraction of steel balls of = 0.2, we estimate N = Vi/Vs = 1600 balls of 1 mm
diameter in the 2 cm diameter spherical implant (volume Vi = 4.2cm3). Assuming the steel balls are
all in the same field conditions, then each ball must produce the same power absorption of Ps = Pi/N
= 2.5-16×10-4 W per steel ball for the range of blood perfusion studied. Using equation (6) with  =
107 S/m, = 100 at f = 100 kHz and Rs = 0.5 mm, we find the magnetic field amplitude required to
generate that amount of heating ranges from Hm = 163-414 A/m for the range of perfusion analyzed.
Table 1. Theoretical power deposition from ferromagnetic spheres within the tumor bed implant required to
heat a surrounding 5 mm shell of at-risk tissue target to a minimum of 40°C, for a bracketing range of
perfusion levels.

Tissue Blood
Perfusion

Temperature Range
in Tumor Bed

Power Density
in Implant

Power
Absorbed in
Implant

Power
Absorbed in
each Sphere

Required
Magnetic
Field

ωb (kg/s/m3)

Ttarget (°C)

Qi (W/m3)

Pi (W)

Ps (W)

Hm (A/m)

None

0

40.0-42.1

9.45×104

0.4

2.5×10-4

163

Basal

0.7

40.0-43.8

1.80×105

0.8

4.7×10-4

224

Active

6.2

40.0-50.3

6.14×105

2.6

1.6×10-3

414

Figure 7 shows the results of laboratory heating of a spherical implant of 2 cm diameter made of
self-curing silicone impression mold material with 1 mm diameter steel balls added at the specified
volume ratio (4%, 9% and 19%). The Curie temperature of steel is very high (~770C) so that
thermoregulation at the desired target temperature does not occur with this ferromagnetic heat
source. Instead, final temperature of the steel balls will depend on magnetic field strength which
must be adjusted during treatment to maintain appropriate implant temperature. For a volume
fraction of 19% ferromagnetic filler, it takes just over 2 minutes to increase the implant temperature
by 10°C in a 500 A/m field. Higher or lower volume fractions will affect the heating rate as shown
in figure 7, or equivalent heating rates could be achieved by adjusting the magnetic field strength.
Since the thermal conductivity of silicone is a little less than half that of tissue and orders of
magnitude lower than the steel, the 1 mm diameter balls should be located no more than 1-2 mm
apart to minimize variation in implant temperature between balls. A volume fill ratio of 19% or
more will produce rapid heating with little temperature variation across the implant.
Volume %
19%
9%
4%

Mass %
60%
40%
20%

Figure 7 Experimental results of applying 20 W to a laboratory 100 KHz magnetic induction
heating system coupled to a 2 cm diameter implant filled with three different volume (mass)
fractions of ferromagnetic steel balls distributed within the silicone base.

Discussion
The results of a 96 patient pilot study establish the clinical potential of a new multimodality
treatment approach for laryngeal cancer. The treatment consists of combining partial larynx

resection surgery with sequential HDR brachytherapy, which is delivered to the resection cavity
from within a silicone gel implant that is formed intraoperatively to fit the tumor bed. All patients
received preoperative external beam radiotherapy concurrently with systemic chemotherapy. In
patients with tumor reduction from initial therapy, an HDR dose was delivered via afterloading
catheters inserted into the tumor bed implant. As a consequence, this procedure allowed reduction
in the resection volume and improved the likelihood of preserving organ function.
The excellent clinical results relate to patient selection as this study considers only the highly
favorable patient group consisting of just 48 of the initial 96 patient group. Radiation Therapy
Oncology Group (RTOG) 91-11 showed 5 year overall survival ranging from 53.8% to 58.1% for
three different treatment protocols in patients with Stage III or IV glottic or supraglottic squamous
cell cancers (Forastiere et al., 2013). The study considered in this work reports a much higher
clinical response rate, with 5 year relapse free survival of 95.8%. In the RTOG study, 5 year larynx
preservation ranged from 65.8% to 83.6% for the three protocols, whereas the larynx was preserved
in all but the two treatment failures (95.8%) in the current study. While there are limitations in
extrapolating results between different study populations, the findings suggest this approach may
benefit a wider range of patients when combined with hyperthermia.
On critical review, the results

obtained with this novel technique should be considered a

demonstration of feasibility rather than proof of efficacy of this approach. First of all, the trial was
conducted on a specially selected group of patients including only T3 tumors with clinically and
radiographically negative cervical lymph nodes, and only in those patients whose tumor decreased
after initial external beam radiotherapy delivered concurrently with systemic chemotherapy. These
selection criteria may explain the high 5-year survival rate, which is not easily compared to
previously published studies of organ preservation techniques for laryngeal cancer. Nevertheless,
initial success with this method supports the feasibility of a new organ preservation regimen, at least
in cases with intermediate risk laryngeal cancer.
This new clinical procedure was conceived and the first clinical trial performed in Kemerovo,
Russia. One of the advantages of this method stems from its potential to be readily combined with
intraoperative contact hyperthermia for additional improvement in patient outcomes. This type of
hyperthermia is akin to ferromagnetic thermoseed hyperthermia except its aim is not to heat a large
tumor as in previous studies (Mack et al., 1993, Stauffer et al., 1984a, Tucker et al., 2000,
Brezovich et al., 1984), but rather just a thin shell (~5 mm) of at-risk tissue surrounding a tumor
resection cavity. Precise localization of treatment to just the tumor bed can be achieved using a
custom fitting implant to deliver both brachytherapy and hyperthermia. In order to generate heat, we
propose to distribute small 1 mm spherical ferromagnetic particles uniformly throughout the interior
of a patient-customized silicone implant that fills the tumor resection cavity. This contrasts with the
traditional use of ferromagnetic implant arrays which are highly invasive and require numerous

closely spaced interstitial needles or catheters throughout an intact tumor volume (Chin and
Stauffer, 1991, Stauffer et al., 1984b, Stauffer et al., 1984a, Mack et al., 1993, Tompkins et al.,
1994). That multiple needle implant procedure is time intensive for the surgeon and painful for the
patient, and if the spacing is increased from 1.0 towards 1.5 cm for clinical practicality, the ability
to achieve homogenous heating within the target volume becomes compromised (Chin and Stauffer,
1991). The use of 1 mm ferromagnetic spheres packed close together within the implant allows
uniform heating of tumor bed in contact with the essentially equi-temperature implant surface. This
compares favorably with the extreme peaks and valleys of temperature found within a
ferromagnetic seed implant array (Chin and Stauffer, 1991).
For practical use of this thermobrachytherapy approach, the surgical and brachytherapy aspects
can remain the same as the clinical trial described above (Vasil'chenko et al., 2011), while adding a
hyperthermia treatment immediately before or after the HDR brachytherapy. Target tissue
temperatures may be controlled during treatment in one of two ways. Initially, to maintain the
desired implant surface temperature sensors may be placed inside the implant catheters for
continuous monitoring and feedback control of magnetic field strength. Eventually, the steel balls
may be replaced with ferromagnetic balls that undergo their Curie point transition at a temperature
established during initial clinical investigations to achieve sufficient thermal dose throughout the
target volume. With a self-regulating Curie point implant, thermal treatments would be possible
with or without temperature sensors for monitoring implant temperature during heating.
The effect of blood perfusion on temperature distribution was analyzed based on a wide range of
muscle tissue properties (0-6.2 kg/s/m3) that is representative of most soft tissues in the human body
(Jain and Wardhartley, 1984, Waterman et al., 1987). For the initially proposed 45C implant
surface temperature, the therapeutic penetration depth was estimated to be between 3.2-10 mm
(figure 6a), which should provide the desired thermal boost to at-risk tissues for all but the highest
perfusion rate. To accommodate use of this approach in highly perfused tumor bed, implant
temperatures were recalculated (figure 6b) to ensure penetration of the desired minimum therapeutic
temperature of 40C out to at least 5 mm radial distance from the implant. In the case of high
implant temperatures needed for high perfusion tissue, some overheating of 1-2 mm of target tissue
immediately adjacent to the implant surface is likely.

Slight overtreatment of at-risk tissue

immediately adjacent to the implant is not an unexpected “toxicity” of brachytherapy implants. For
sensitive tissue locations where this is a concern, the oncologist may limit temperatures to 45-46C
at the implant surface even for high perfusion cases, assuming that tissue perfusion will be reduced
during treatment. Moreover, adding hyperthermia to brachytherapy may allow some reduction of
radiation dose, potentially limiting radiation-related side effects.
The thermal dose is quantified in terms of CEM43, which stands for cumulative equivalent
minutes at 43°C. Considering the thermal dose delivered with the aforementioned approach, the

maximum CEM43 dose in “normal tissue” at r = 5 mm from the implant is the same as the
minimum CEM43 dose at the target periphery. The goal considered in figure 6 simulations is to
cover the target with a minimum thermal dose of 40C for 60 min, which corresponds to a CEM43
of approximately 1 equivalent minute. Depending on the goal of the radiation oncologist, the
maximum thermal dose to the target volume would be 45C for 60 min (figure 6a), which
corresponds to a CEM43 of 240 equivalent minutes. However, if acceptable clinically, a much
higher dose might be used adjacent to the implant surface to accommodate cases with very high
blood perfusion. Regardless of perfusion level, the maximum CEM43 thermal dose expected in
normal tissue at distances greater than 5 mm from the implant is about 1 equivalent minute.
Finally, we determined the required magnetic field to guarantee a minimum 40°C throughout the
tumor bed target, yielding 163-414 A/m depending on heat removal from blood perfusion. As has
been reported previously, this field is well tolerated clinically even in large patients, effectively
coupling energy into implanted ferromagnetic seeds while minimizing undesired heating of normal
tissues (Mack et al., 1993, Stauffer et al., 1994). In practice, the field strength should be determined
for the worst case high perfusion scenario while using ferroseed materials that undergo their Curie
point transition from magnetic to non-magnetic at the desired treatment temperature (Brezovich et
al., 1984, Cetas et al., 1998, Kobayashi et al., 1986). Above this minimum threshold field strength,
such ferroseeds will self-regulate temperature close to their inherent Curie point regardless of
excess field, leading to more uniform tumor heating in a variable perfusion environment without the
need to measure internal source temperatures or adjust power of the magnetic field. Moreover, the
use of Curie point thermoregulating seeds maintains uniform temperatures within the implant even
though the ferromagnetic balls are not in equal conditions, since the outer balls partially shield the
inner ones such that they do not receive the same magnetic field.
According to our calculations, the estimated maximum required field strength of Hm < 413 A/m
is about 50 times less than the intensity of the alternating magnetic fields required for magnetic
fluid hyperthermia (Ivkov, 2013, Petryk et al., 2013). This simplifies the equipment for generating
the magnetic field and effectively eliminates direct eddy current heating of normal neck tissues.
This ensures the treatment will be safe and well-tolerated clinically, even better than previously
reported clinical trials of ferromagnetic implant hyperthermia (Stea et al., 1990, Stea et al., 1994,
Tucker et al., 2000, Mack et al., 1993). Although practical tumor bed implants will have
considerably more complex shape than the simple spherical implant studied in this work, the ability
to heat up to 10 mm radially around a large implant and the low field required to heat the implant
demonstrate the potential for this hyperthermia approach.

Conclusions
A new method for treatment of locally advanced head and neck tumors was applied to a preselected group of 48 male patients with stage T3N0M0 cancer of the larynx. The method involves
organ-preserving surgery followed by high-dose-rate brachytherapy of the resection cavity wall
delivered from within an intraoperatively formed custom silicone implant that fills the tumor bed.
The implant also maintains position of regularly spaced brachytherapy catheters for several hours to
deliver a post-operative brachytherapy dose to the tumor bed. In a selected group of patients with
disease responsive to initial external beam radiation delivered concurrently with systemic
chemotherapy, the 5-year recurrence-free survival rate was 95.8%. Improvement in long term
clinical outcome is anticipated in less favorable locally advanced head and neck cancers by adding
local hyperthermia to the organ sparing surgery and brachytherapy. Experiments were conducted
which confirm a theoretical analysis that demonstrates the feasibility of applying effective
hyperthermia to at-risk tissues surrounding a resection cavity using inductive heating of
ferromagnetic spheres dispersed uniformly within the polymeric matrix of a tumor bed implant, as a
means to enhance brachytherapy response.

Acknowledgements
The authors wish to acknowledge the support of the institutions involved in these studies. The
authors alone are responsible for the content and writing of the paper.

References
Al-Bataineh O, Jenne J & Huber P 2011. Clinical and future applications of high intensity focused ultrasound
in cancer. Cancer Treat Rev.
Amichetti M, Graiff C, Fellin G, Pani G, Bolner A, Maluta S & Valdagni R 1993. Cisplatin, hyperthermia, and
radiation (trimodal therapy) in patients with locally advanced head and neck tumors: A phase i-ii
study. International Journal of Radiation Oncology Biology Physics, 26, 801-807.
Arcangeli G, Lombardini PP, Lovisolo GA, Marsiglia G & Piattelli M 1984. Focusing of 915 mhz
electromagnetic power on deep human tissues: A mathematical model study. IEEE Trans Biomed
Eng, 31, 47-52.
Atkinson WJ, Brezovich IA & Chakraborty DP 1984. Usable frequencies in hyperthermia with thermal seeds.
IEEE Trans Biomed Eng, 31, 70-5.
Brezovich IA, Atkinson WJ & Chakraborty DP 1984. Temperature distributions in tumor models heated by
self-regulating nickel-copper alloy thermoseeds. Medical Physics, 11, 145-52.
Burton CV, Hill M & Walker AE 1971. The rf thermoseed--a thermally self-regulating implant for the
production of brain lesions. IEEE Transactions on Biomedical Engineering, 18, 104-109.
Canters RA, Wust P, Bakker JF & Van Rhoon GC 2009. A literature survey on indicators for characterisation
and optimisation of sar distributions in deep hyperthermia, a plea for standardisation. Int J
Hyperthermia, 25, 593-608.
Cetas TC, Gross EJ & Contractor Y 1998. A ferrite core/metallic sheath thermoseed for interstitial thermal
therapies. IEEE Transactions on Biomedical Engineering, 45, 68-77.

Chen D, Xia R, Chen X, Shafirstein G, Corry PM, Griffin RJ, Penagaricano JA, Tulunay-Ugur OE & Moros EG
2011. Sonoknife: Feasibility of a line-focused ultrasound device for thermal ablation therapy. Med
Phys, 38, 4372-85.
Chin RB & Stauffer PR 1991. Treatment planning for ferromagnetic seed heating. Int J Radiat Oncol Biol
Phys, 21, 431-9.
Datta NR, Puric E, Klingbiel D, Gomez S & Bodis S 2016a. Hyperthermia and radiation therapy in
locoregional recurrent breast cancers: A systematic review and meta-analysis. Int J Radiat Oncol
Biol Phys, 94, 1073-87.
Datta NR, Rogers S, Ordonez SG, Puric E & Bodis S 2016b. Hyperthermia and radiotherapy in the
management of head and neck cancers: A systematic review and meta-analysis. Int J Hyperthermia,
32, 31-40.
Dewhirst M, Stauffer P, Das S, Craciunescu O & Vujaskovic Z 2015. Hyperthermia. In: Ll G & Je T (eds.)
Clinical Radiation Oncology 4th Ed. Philadelphia: Elsevier.
Falk MH & Issels RD 2001. Hyperthermia in oncology. Int J Hyperthermia, 17, 1-18.
Fatehi D & Van Rhoon GC 2008. Sar characteristics of the sigma-60-ellipse applicator. International Journal
of Hyperthermia, 24, 347-56.
Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge
JA, et al. 2013. Long-term results of rtog 91-11: A comparison of three nonsurgical treatment
strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol, 31,
845-52.
Gross EJ, Cetas TC, Stauffer PR, Liu RL & Lumori ML 1990. Experimental assessment of phased-array heating
of neck tumours. Int J Hyperthermia, 6, 453-74.
Haar GT & Coussios C 2007. High intensity focused ultrasound: Past, present and future. Int J Hyperthermia,
23, 85-7.
Hasgall PA, Di Gennaro F, Neufeld E, Gosselin MC, Payne D, Klingenböck A & Kuster N January 13th, 2015.
It'is database for thermal and electromagnetic parameters of biological tissues, version 2.6.
Holsinger FC 2008. Swing of the pendulum: Optimizing functional outcomes in larynx cancer. Curr Oncol
Rep, 10, 170-5.
Hurwitz M & Stauffer P 2014. Hyperthermia, radiation and chemotherapy: The role of heat in
multidisciplinary cancer care. Semin Oncol, 41, 714-29.
Hurwitz MD, Ghanouni P, Kanaev SV, Iozeffi D, Gianfelice D, Fennessy FM, Kuten A, Meyer JE, Leblang SD,
Roberts A, et al. 2014. Magnetic resonance-guided focused ultrasound for patients with painful
bone metastases: Phase iii trial results. J Natl Cancer Inst, 106.
Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, Abdel-Rahman S, Daugaard S, Salat C,
Wendtner CM, et al. 2010. Neo-adjuvant chemotherapy alone or with regional hyperthermia for
localised high-risk soft-tissue sarcoma: A randomised phase 3 multicentre study. Lancet Oncol.
Ivkov R 2013. Magnetic nanoparticle hyperthermia: A new frontier in biology and medicine? Int J
Hyperthermia, 29, 703-5.
Jain RK & Wardhartley K 1984. Tumor blood-flow - characterization, modifications, and role in
hyperthermia. Ieee Transactions on Sonics and Ultrasonics, 31, 504-526.
Kobayashi T, Kida Y, Tanaka T, Kageyama N & Kobayashi H 1986. Magnetic induction hyperthermia for brain
tumor using ferromagnetic implant with low curie temperature. I. Experimental study. Journal of
Neuro-Oncology, 4, 175-181.
Kouloulias V, Triantopoulou S, Vrouvas J, Gennatas K, Ouzounoglou N, Kouvaris J, Karaiskos P, Aggelakis P,
Antypas C, Zygogianni A, et al. 2014. Combined chemoradiotherapy with local microwave
hyperthermia for treatment of t3n0 laryngeal carcinoma: A retrospective study with long-term
follow-up. Acta Otorhinolaryngol Ital., 34, 167-73.
Mack CF, Stea B, Kittelson JM, Shimm DS, Sneed PK, Phillips TL, Swift PS, Luk K, Stauffer PR, Chan KW, et al.
1993. Interstitial thermoradiotherapy with ferromagnetic implants for locally advanced and
recurrent neoplasms. International Journal of Radiation Oncology Biology Physics, 27, 109-115.
Obinata K, Ohmori K, Shirato H & Nakamura M 2007. Experience of high-dose-rate brachytherapy for head
and neck cancer treated by a customized intraoral mold technique. Radiat Med, 25, 181-6.
Osintsev AM, Majtakov AL, Vasil’chenko IL, Vinogradov VM & Rynk VV. 2013. Method for local induction
heating of biological tissues. Russia patent application RU 2497489 C1.

Overgaard J, Gonzales Gonzales D, Hulshof MCCH, Arcangeli G, Dahl O, Mella O & Bentzen SM 1996.
Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma.
A multicentre randomized trial by the european society for hyperthermia oncology. International
Journal of Hyperthermia, 12, 3-20.
Paulides MM, Bakker JF, Linthorst M, Van Der Zee J, Rijnen Z, Neufeld E, Pattynama PM, Jansen PP,
Levendag PC & Van Rhoon GC 2010. The clinical feasibility of deep hyperthermia treatment in the
head and neck: New challenges for positioning and temperature measurement. Phys Med Biol, 55,
2465-80.
Paulides MM, Bakker JF, Neufeld E, Van Der Zee J, Jansen PP, Levendag PC & Van Rhoon GC 2007a. The
hypercollar: A novel applicator for hyperthermia in the head and neck. International Journal of
Hyperthermia, 23, 567-76.
Paulides MM, Bakker JF, Zwamborn AP & Van Rhoon GC 2007b. A head and neck hyperthermia applicator:
Theoretical antenna array design. International Journal of Hyperthermia, 23, 59-67.
Pennes HH 1948. Analysis of tissue and arterial blood temperatures in the resting human forearm. Journal
of Applied Physiology, 1, 93-122.
Petryk AA, Giustini AJ, Gottesman RE, Kaufman PA & Hoopes PJ 2013. Magnetic nanoparticle hyperthermia
enhancement of cisplatin chemotherapy cancer treatment. Int J Hyperthermia, 29, 845-51.
Rodrigues D, Pereira J, Limão-Vieira P, Stauffer P & Maccarini P 2013. Study of the one dimensional and
transient bioheat transfer equation: Multilayer solution development and applications.
International Journal of Heat and Mass Transfer, 62, 153-162.
Rudolph E, Dyckhoff G, Becher H, Dietz A & Ramroth H 2011. Effects of tumour stage, comorbidity and
therapy on survival of laryngeal cancer patients: A systematic review and a meta-analysis. Eur Arch
Otorhinolaryngol, 268, 165-79.
Sekins KM, Lehmann JF, Esselman P, Dundore D, Emery AF, Delateur BJ & Nelp WB 1984. Local muscle
blood-flow and temperature responses to 915mhz diathermy as simultaneously measured and
numerically predicted. Archives of Physical Medicine and Rehabilitation, 65, 1-7.
Sneed PK, Stauffer PR, Mcdermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L,
Malec MK, et al. 1998. Survival benefit of hyperthermia in a prospective randomized trial of
brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 40,
287-95.
Sperry SM, Rassekh CH, Laccourreye O & Weinstein GS 2013. Supracricoid partial laryngectomy for primary
and recurrent laryngeal cancer. JAMA Otolaryngol Head Neck Surg, 139, 1226-35.
Stauffer PR, Cetas TC, Fletcher AM, Deyoung DW, Dewhirst MW, Oleson JR & Roemer RB 1984a.
Observations on the use of ferromagnetic implants for inducing hyperthermia. IEEE Trans Biomed
Eng, 31, 76-90.
Stauffer PR, Cetas TC & Jones RC 1984b. Magnetic induction heating of ferromagnetic implants for inducing
localized hyperthermia in deep-seated tumors. IEEE Trans Biomed Eng, 31, 235-51.
Stauffer PR, Diederich CJ & Seegenschmiedt MH 1995. Interstitial heating technologies. In: Seegenschmiedt
MH, Fessenden P & Vernon CC (eds.) Thermoradiotherapy and thermochemotherapy: Volume 1,
biology, physiology and physics. Berlin, New York: Springer-Verlag.
Stauffer PR, Sneed PK, Hashemi H & Phillips TL 1994. Practical induction heating coil designs for clinical
hyperthermia with ferromagnetic implants. IEEE Trans Biomed Eng, 41, 17-28.
Stea B, Cetas TC, Cassady JR, Guthkelch AN, Iacono R, Lulu B, Lutz W, Obbens E, Rossman K, Seeger J, et al.
1990. Interstitial thermoradiotherapy of brain tumors: Preliminary results of a phase i clinical trial.
International Journal of Radiation Oncology Biology Physics, 19, 1463-1471.
Stea B, Rossman K, Kittelson J, Shetter A, Hamilton A & Cassady JR 1994. Interstitial irradiation versus
interstitial thermoradiotherapy for supratentorial malignant gliomas: A comparative survival
analysis. International Journal of Radiation Oncology Biology Physics, 30, 591-600.
Tempany CM, Mcdannold NJ, Hynynen K & Jolesz FA 2011. Focused ultrasound surgery in oncology:
Overview and principles. Radiology, 259, 39-56.
Togni P, Rijnen Z, Numan WC, Verhaart RF, Bakker JF, Van Rhoon GC & Paulides MM 2013. Electromagnetic
redesign of the hypercollar applicator: Toward improved deep local head-and-neck hyperthermia.
Phys Med Biol, 58, 5997-6009.
Tompkins DT, Vanderby R, Klein SA, Beckman WA, Steeves RA & Paliwal BR 1994. Effect of interseed
spacing, tissue perfusion, thermoseed temperatures and catheters in ferromagnetic hyperthermia:

Results from simulations using finite element models of thermoseeds and catheters. IEEE Trans
Biomed Eng, 41, 975-85.
Tucker RD, Huidobro C, Larson T & Platz CE 2000. Use of permanent interstitial temperature self-regulating
rods for ablation of prostate cancer. J Endourol, 14, 511-7.
Valdagni R & Amichetti M 1994. Report of long-term follow-up in a randomized trial comparing radiation
therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage iv head and
neck patients. International Journal of Radiation Oncology Biology Physics, 28, 163-169.
Van Rhoon GC, Van Der Heuvel DJ, Ameziane A, Rietveld PJ, Volenec K & Van Der Zee J 2003.
Characterization of the sar-distribution of the sigma-60 applicator for regional hyperthermia using a
schottky diode sheet. International Journal of Hyperthermia, 19, 642-54.
Vasil'chenko IL, Vinogradov VM, Pastushenko DA, Osintsev AM, Maitakov AL, Rynk VV & Vasil'chenko NV
2013. [use of local induced hyperthermia in the treatment of malignant tumors]. Vopr Onkol, 59,
84-9.
Vasil'chenko IL, Vinogradov VM, Pastushenko DA, Samsonova NN & Iudin AL 2011. [first experience with
intrasurgical brachytherapy in the combined treatment for locally advanced laryngeal cancer]. Vopr
Onkol, 57, 232-5.
Vasil’chenko IL, Pastushenko DA, Kuznetsova TA, Polikarpov AF, Magarill JA, Mal’tsev AA, Judin AL, Cherno
SV & Shegaj TS. 2008. Method for treating malignant tumors of larynx and laryngopharynx. Russia
patent application RU 2322199 C1.
Waterman FM, Nerlinger RE, Moylan DJ, 3rd & Leeper DB 1987. Response of human tumor blood flow to
local hyperthermia. International Journal of Radiation Oncology Biology Physics, 13, 75-82.
Wilkie MD, Lightbody KA, Lythgoe D, Tandon S, Lancaster J & Jones TM 2015. Transoral laser microsurgery
for early and moderately advanced laryngeal cancers: Outcomes from a single centralised united
kingdom centre. Eur Arch Otorhinolaryngol, 272, 695-704.

